Table 2.

Individual follow-up cognitive diagnoses, performances, and baseline demographics for the subgroup of participants with low baseline CSF Aβ₄₂ levels

Participant	Follow-up year 9							Demography			Baseline
Diagnosis	Year of diagnosis	Age	MMSE (points)	Delayed word recall (correct of 10)	AQT (s)∗	Clock test (correct)	Sex	Education (y)	APOE genotype	Aβ42 (ng/L)	T-tau (ng/L)	P-tau (ng/L)	MMSE (points)	Delayed word recall (correct of 10)
A	AD	2012	84	19	3	91	Yes	Female	7.0	3/4	130	97	49	30	7
B	AD	2012	93	21	2	83	No	Female	7.0	3/4	103	102	61	29	9
C	AD	2007†	80	21	0	150	No	Male	9.0	3/4	172	45	26	29	8
D	AD	2010	92	21	0	176	No	Female	13.0	3/3	182	33	11	30	5
E	AD	2007†	83	12	0	184	No	Female	9.0	3/4	85	157	55	30	6
F	DLB	2010†	82	30	7	80	No	Male	18.0	3/3	165	94	45	30	8
G	MCI	2012	83	25	6	121	No	Female	8.0	3/3	90	62	25	30	10
H	MCI	2012	91	28	7	146	Yes	Male	12.5	3/4	139	82	34	28	8
I	Normal	NA	88	29	7	68	Yes	Male	16.5	3/3	77	70	62	30	8
J	Normal	NA	81	28	6	50	Yes	Female	15.0	3/3	127	145	74	28	7
K	Normal	NA	81	30	9	71	Yes	Female	7.0	3/4	121	139	69	30	10
L	Normal	NA	72	29	10	40	Yes	Male	10.0	3/3	92	63	45	27	9

Abbreviations: CSF, cerebrospinal fluid; Aβ₄₂, β-amyloid 42; MMSE, mini-mental state examination; AQT, a quick test; APOE, apolipoprotein E; T-tau, total tau; P-tau, phosphorylated tau; AD, Alzheimer's disease; DLB, dementia with Lewy bodies; MCI, mild cognitive impairment; NA, not applicable.

NOTE. Year of diagnosis state when the participant was given its first cognitive diagnosis.

^∗Color-form version of AQT is stated (reference value <70 s).

^†Year of preceding MCI diagnosis.